Answers are grounded in this paper and cite their sources.
The objective of this research was the development and evaluation of 203 Pb-labelled panitumumab ( 203 Pb-PSC-panitumumab) as an immuno-SPECT radioligand for the detection of EGFR + head and neck squamous cell carcinoma (HNSCC) in a patient-derived xenograft (PDX) mouse model . The 51.9 h physical half-life and favourable γ-emission (279 keV; 81%) of 203 Pb offer an excellent opportunity for developing immuno-SPECT radioligands. Moreover, 203 Pb has a complementary therapeutic radionuclide ( 212 Pb), making 203 Pb and 212 Pb an ideal matched radiotheranostic pair. Radiolabeling of panitumumab was performed at a pH of 5.0 and room temperature for 5–10 min with [ 203 Pb]Pb(OAc) 2 , and the incorporation efficiency was determined using radio-TLC. 203 Pb-PSC-panitumumab (~ 10 MBq, 140 μl of saline) was injected into the tail vein of NRG mice bearing subcutaneous (s.c.) HNSCC patient-derived xenografts (PDX). SPECT/CT images were acquired at 48 and 120 h post-injection. For biodistribution studies, mice were euthanized five days after 203 Pb-panitumumab injection. The tumour and normal tissues were collected and weighed, and uptake of 203 Pb was measured in a γ-counter. The uptake was calculated as the percent injected dose per gram of each tissue (ID%/g). Blocking experiments were performed by pretreating a group of mice (n = 5) with 1 mg of panitumumab 1 h before administering 203 Pb-PSC-panitumumab. 4–5 chelators of a new lead-specific chelator (PSC) were attached per antibody; radiolabeling efficiency was 99.2 ± 0.7%. The isolated radiochemical yield of 203 Pb-PSC-panitumumab was 41.4 ± 8% (n = 5), and the molar activity was 1.2 ± 0.35 GB/mg. SPECT imaging and biodistribution confirmed high accumulation and retention of 203 Pb-PSC-panitumumab in the tumour (26% ID/g) at 120 h post-injection (p.i.), which could be reduced to 6.2%ID/g at 120 h p.i. by predosing with panitumumab (1 mg) confirming EGFR specificity of 203 Pb-PSC-panitumumab uptake. Panitumumab was successfully and reproducibly labelled with 203 Pb in high radiochemical purity using the chelator PSC-NCS. 203 Pb-PSC-panitumumab was specifically accumulated and retained in EGFR + tumours in NRG mice with s.c. HNSCC PDX. 203 Pb-PSC-panitumumab is a suitable immuno-SPECT radioligand for imaging EGFR + tumours and has great potential for combining with 212 Pb-PSC-panitumumab in a radiotheranostic strategy for imaging and treating HNSCC.
No takes yet. Share an insight, caveat, or question.
Sarrami et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: